natgillin/translations-raw huggingface dataset:
Docetaxel Winthrop 20 mg/1 ml concentrate for solution for infusion requires NO prior dilution with a solvent and is ready to add to the infusion solution.
Docetaxel Winthrop 20 mg/1 ml koncentrat za otopinu za infuziju NE zahtijeva prethodno razrjeđivanje otapalom te se može odmah dodati u infuzijsku vrećicu.
Docetaxel Winthrop 20 mg/1 ml sterile concentrate docetaxel
Docetaxel Winthrop 20 mg/1 ml sterilni koncentrat docetaksel
Docetaxel Winthrop 80 mg/4 ml concentrate for solution for infusion
Docetaxel Winthrop 80 mg/4 ml koncentrat za otopinu za infuziju
Docetaxel Winthrop 80 mg/4 ml concentrate for solution for infusion docetaxel
Docetaxel Winthrop 80 mg/4 ml koncentrat za otopinu za infuziju docetaksel
Docetaxel Winthrop 80 mg/4 ml concentrate for solution for infusion requires NO prior dilution with a solvent and is ready to add to the infusion solution.
Docetaxel Winthrop 80 mg/4 ml koncentrat za otopinu za infuziju NE zahtijeva prethodno razrjeđivanje otapalom te se može odmah dodati u infuzijsku otopinu.
Docetaxel Winthrop 80 mg/4 ml concentrate for solution for infusion requires NO prior dilution with a solvent and is ready to add to the infusion solution.
Docetaxel Winthrop 80 mg/4 ml koncentrat za otopinu za infuziju NE zahtijeva prethodno razrjeđivanje otapalom te se može odmah dodati u infuzijsku vrećicu.
Docetaxel Winthrop 80 mg/4 ml sterile concentrate docetaxel
Docetaxel Winthrop 80 mg/4 ml sterilni koncentrat docetaksel
Docetaxel Winthrop as single agent
Docetaxel Winthrop u monoterapiji
Docetaxel Winthrop concentrate for solution for infusion is a pale yellow to brownish-yellow solution.
Docetaxel Winthrop koncentrat za otopinu za infuziju je blijedo žuta do smeđežuta otopina.
Docetaxel Winthrop contains alcohol.
Docetaxel Winthrop sadrži alkohol.
Docetaxel Winthrop contains ethanol (alcohol)
Docetaxel Winthrop sadrži etanol (alkohol)
Docetaxel Winthrop has been prescribed by your doctor for the treatment of breast cancer, special forms of lung cancer (non-small cell lung cancer), prostate cancer, gastric cancer or head and neck cancer:
Docetaxel Winthrop Vam je propisao liječnik za liječenje karcinoma dojke, posebnih oblika karcinoma pluća (karcinom nemalih stanica pluća), karcinoma prostate, karcinoma želuca ili karcinoma glave i vrata:
Docetaxel Winthrop in combination with capecitabine
Docetaxel Winthrop u kombinaciji s kapecitabinom
Docetaxel Winthrop in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy.
Docetaxel Winthrop u kombinaciji s kapecitabinom indiciran je za liječenje bolesnika s lokalno uznapredovalim ili metastatskim karcinomom dojke nakon neuspjeha terapije s drugim citostaticima.
Docetaxel Winthrop in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.
Docetaxel Winthrop u kombinaciji sa cisplatinom i 5-fluorouracilom je indiciran za indukcijsko liječenje bolesnika s lokalno uznapredovalim karcinomom skvamoznih stanica glave i vrata.
Docetaxel Winthrop in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.
Docetaxel Winthrop u kombinaciji s cisplatinom i 5-fluorouracilom je indiciran za liječenje bolesnika s metastatskim adenokarcinomom želuca, uključujući adenokarcinom gastroezofagealnog spoja, koji nisu prethodno primali kemoterapiju za metastatsku bolest.
Docetaxel Winthrop in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer, in patients who have not previously received chemotherapy for this condition.
Docetaxel Winthrop u kombinaciji s cisplatinom indiciran je za liječenje bolesnika s neoperabilnim, lokalno uznapredovalim ili metastatskim karcinomom nemalih stanica pluća, koji nisu ranije primali kemoterapiju za tu bolest.
Docetaxel Winthrop in combination with doxorubicin
Docetaxel Winthrop u kombinaciji s doksorubicinom
Docetaxel Winthrop in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:
Docetaxel Winthrop u kombinaciji s doksorubicinom i ciklofosfamidom indiciran je za adjuvantno liječenje bolesnika s:
Docetaxel Winthrop in combination with doxorubicin and cyclophosphamide: adjuvant therapy
Docetaxel Winthrop u kombinaciji s doksorubicinom i ciklofosfamidom: adjuvantno liječenje
Docetaxel Winthrop in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.
Docetaxel Winthrop u kombinaciji s doksorubicinom indiciran je za liječenje bolesnika s lokalno uznapredovalim ili metastatskim karcinomom dojke koji nisu ranije liječeni citostaticima za tu bolest.
Docetaxel Winthrop in combination with platinum agents in chemotherapy-naïve patients
Docetaxel Winthrop u kombinaciji s derivatima platine u bolesnika koji nisu ranije primali kemoterapiju
Docetaxel Winthrop in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.
Docetaxel Winthrop u kombinaciji s prednizonom ili prednizolonom indiciran je za liječenje bolesnika s metastatskim karcinomom prostate refraktornim na hormonsko liječenje.
Docetaxel Winthrop in combination with trastuzumab
Docetaxel Winthrop u kombinaciji s trastuzumabom
Docetaxel Winthrop in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours over express HER2 and who previously have not received chemotherapy for metastatic disease.
Docetaxel Winthrop u kombinaciji s trastuzumabom indiciran je za liječenje bolesnika s metastatskim karcinomom dojke i prekomjerno izraženim HER2, koji nisu ranije primali kemoterapiju za metastatsku bolest.
Docetaxel Winthrop is an antineoplastic agent and, as with other potentially toxic compounds, caution should be exercised when handling it and preparing Docetaxel Winthrop solutions.
Docetaxel Winthrop je antineoplastična tvar te se, kao što je slučaj i sa svim ostalim potencijalno toksičnim spojevima, mora s njime oprezno rukovati u pripremi otopine Docetaxel Winthrop.
Docetaxel Winthrop is an antineoplastic agent and, as with other potentially toxic compounds, caution should be exercised when handling it and preparing Docetaxel Winthrop solutions.
Docetaxel Winthrop je antineoplastična tvar te se, kao što je slučaj i sa svim ostalim potencijalno toksičnim spojevima, mora s njime oprezno rukovati u pripremi otopine lijeka Docetaxel Winthrop.
Docetaxel Winthrop is indicated for the treatment of patients with locally advanced or metastatic non- small cell lung cancer after failure of prior chemotherapy.
Docetaxel Winthrop je indiciran za liječenje bolesnika s lokalno uznapredovalim ili metastatskim karcinomom nemalih stanica pluća nakon neuspjeha prethodne kemoterapije.
Docetaxel Winthrop is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior chemotherapy.
Docetaxel Winthrop je indiciran za liječenje bolesnika s lokalno uznapredovalim ili metastatskim karcinomom nemalih stanica pluća nakon neuspjeha prethodne kemoterapije.
Docetaxel Winthrop monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy.
Docetaxel Winthrop kao monoterapija indiciran je za liječenje bolesnika s lokalno uznapredovalim ili metastatskim karcinomom dojke nakon neuspjeha terapije drugim citostaticima.
Docetaxel Winthrop must NOT be administered if you are pregnant unless clearly indicated by your doctor.
Docetaxel Winthrop NE SMIJETE primati ako ste trudni, osim ako to liječnik nije izričito propisao.
Docetaxel Winthrop was administered as a 1-hour infusion, all other medicinal products were given intraveinously on day 1 every three weeks.
Docetaxel Winthrop se primjenjivao u obliku jednosatne infuzije, a svi ostali lijekovi davali su se intravenski na dan 1 svaka tri tjedna.
Docetaxel Winthrop will be given by infusion into one of your veins (intravenous use).
Docetaxel Winthrop ćete dobiti infuzijom u jednu od vena (intravenska primjena).
Docetaxel1 n = 94
Docetaksel1 n = 94
doctor immediately.
lijek i odmah se javite svom liječniku.
Doctor's telephone:
Telefonski broj liječnika:
Doctor:.......................…………………… Tel:...................…………
Doktor:.......................…………………… Tel:...................
Doctor:.......................…………………… Tel:...................…………
Liječnik:.......................…………………… Tel.:...................
Doctor:.......................……………………………………………
Ime liječnika:.......................
Doctors are aware of this possibility and have emergency treatment available for use in such cases.
Liječnici su svjesni te mogućnosti, zbog čega imaju spremno liječenje za hitne slučajeve.
Doctors are aware of this possibility and have emergency treatment available for use in such cases.
Liječnici su svjesni te mogućnosti, zbog čega za takve slučajeve imaju spremno hitno liječenje.
Doctors can also be provided with a home administration training pack, which includes materials for doctors on how to train patients who will inject themselves with Nplate at home, and materials for patients on how to prepare the medicine for injection.
Liječnicima također treba dostaviti komplet za obuku za kućno ubrizgavanje, koji uključuje materijale za liječnike o tome kako obučiti bolesnike koji će si sami ubrizgavati Nplate kod kuće, kao i materijale za bolesnike o tome kako pripremiti lijek za ubrizgavanje.
Doctors may recommend a lower dose or a break from treatment if these values change or if patients have certain side effects.
Liječnici mogu preporučiti manju dozu ili prekid terapije ako se ove vrijednosti promjene ili ako bolesnici imaju određene nuspojave.
Doctors prescribing Leflunomide Winthrop need to be aware of the risk of liver problems associated with the medicine.
Liječnici koji propisuju lijek Leflunomide Winthrop moraju biti upoznati s rizikom oštećenja funkcije jetre, koji je povezan s ovim lijekom.
Doctors prescribing this medicine must have experience with methotrexate and understand how it works.
Liječnici koji propisuju ovaj lijek moraju imati iskustva s metotreksatom i razumjeti kako on djeluje.
Doctors should also periodically assess patients with chronic ITP who still have a spleen to see if they require surgery.
Liječnici također trebaju periodički ispitati stanje bolesnika s kroničnim ITP-om kojima slezena još nije odstranjena kako bi se utvrdilo treba li ih podvrgnuti operaciji.
Doctors should check the patient’s liver before starting treatment with Tasmar and then regularly during treatment.
Liječnici moraju pregledati jetru bolesnika prije početka liječenja lijekom Tasmar te zatim redovito tijekom liječenja.
Doctors should make decisions on whether to use Ebilfumin in babies of this age based on the severity of the disease caused by the flu virus and the baby’s state of health, to ensure that the baby is likely to benefit from the medicine.
Liječnici trebaju donijeti odluku o primjeni Ebilfumina u dojenčadi te dobi na temelju težine bolesti prouzročene virusom gripe i zdravstvenog stanja dojenčeta kako bi se zajamčila korist od primjene lijeka.
Doctors should monitor kidney function carefully in patients with moderately or severely reduced kidney function.
Liječnici moraju pažljivo pratiti funkciju bubrega u bolesnika s umjerenim ili ozbiljnim smanjenjem funkcije bubrega.
Doctors should monitor patients carefully for signs of infection during treatment, and should prescribe RoActemra with caution in patients who have had recurring or long-term infections, or diseases that could increase the risk of infections, such as diverticulitis (a disease affecting the gut) or diabetes.
Liječnici moraju pažljivo pratiti bolesnike kako bi uočili znakove infekcije tijekom liječenja te moraju oprezno propisivati lijek RoActemra u bolesnika koji imaju učestale ili dugotrajne infekcije, odnosno bolesti koje mogu povećati rizik od infekcija, poput divertikulitisa (bolesti koja zahvaća crijeva) ili dijabetesa.
Doctors treating uveitis should also take advice from doctors who have experience of using Humira.
Liječnici koji liječe uveitis trebali bi se također savjetovati s liječnicima koji su iskusni u primjeni lijeka Humira.
Doctor’s office telephone and e-mail:
Telefon i e-adresa liječnikovog ureda:
Document revision date:
Datum revizije dokumenta:
documentation of childbearing potential status
dokumentacija o statusu reproduktivnog potencijala
does not make enough insulin to control the level of sugar in your blood or is not able to use the insulin properly.
ne stvara dovoljno inzulina za regulaciju razine šećera u krvi ili ne može ispravno koristiti inzulin.
does not require antithrombin III for antithrombotic activity.
Za antitrombotsku aktivnost ne iziskuje antitrombin III.
Does not require any special storage conditions.
Ne zahtijeva posebne uvjete čuvanja.
Dofetilide
dofetilid
Dofetilide  (Not studied, potential increase via inhibition of OCT2 transporter)
dofetilid  (interakcija nije ispitivana; moguće je povećanje koncentracije zbog inhibicije prijenosnika OCT2)
Dofetilide  (Not studied, potential increase via inhibition of OCT2 transporter)
koncentracije zbog inhibicije prijenosnika OCT2)
Dofetilide/Dolutegravir
dofetilid 
Dog
Pas.
Dog
Psi.
Dog (2-4.5 kg)
Pas (2 - 4,5 kg)
Dog (11-22 kg)
Pas (> 11 - 22 kg)
Dog (22-50 kg)
Pas (> 22 - 50 kg)
Dog (4.5-11 kg)
Pas (> 4,5 - 11 kg)
Dog and cats
pse i mačke
Dog Cat4
pas mačka4
Dog.
Pas
Dog4
pas4 mačka
Dog4 Cat4
pas4 mačka4
Dogs
6.
Dogs
Mačke, Psi
Dogs
Pas.
Dogs
Pse
Dogs
Psi:
Dogs (male) and ferrets (male)
Psi (mužjaci) i afrički tvorovi (mužjaci)
Dogs (male) and ferrets (male).
Psi (mužjaci) i afrički tvor (mužjaci)
Dogs (male) and ferrets (male).
Psi (mužjaci) i afrički tvorovi (mužjaci)
Dogs (male).
Psi (mužjaci)
dogs 10-20 kg
psi 10-20 kg
dogs 2-10 kg
psi 2-10 kg
Dogs 2-10 kg Dogs 10-20 kg Dogs 20-40 kg Dogs 40-60 kg
psi 2-10 kg psi 10-20 kg psi 20-40 kg psi 40-60 kg
dogs 20-40 kg
psi 20-40 kg
Dogs 2–3.5 kg Dogs >3.5–7.5 kg Dogs >7.5–15 kg Dogs >15–30 kg Dogs >30–60 kg
Psi 2–3,5 kg Psi >3,5–7,5 kg Psi >7,5–15 kg Psi >15–30 kg Psi >30–60 kg
Dogs 2–4 kg Dogs >4–10 kg Dogs >10–25 kg Dogs >25-50 kg
Psi od 2–4 kg Psi >4–10 kg Psi >10–25 kg Psi >25–50 kg
dogs 40-60 kg
psi 40-60 kg
Dogs and cats
pse i mačke
Dogs and cats
Psi i mačke.
Dogs and cats weighing less than 1 kg and ferrets weighing less than 0.8 kg should only be treated after special consideration by the veterinarian.
Mačke i pse koji teže manje od 1 kg kao i afričke tvorove koji teže manje od 0,8 kg treba liječiti ovim proizvodom samo nakon posebnih konzultacija s veterinarom.
Dogs and cats: 8 mg cefovecin/kg body weight (1 ml/10 kg body weight).
Psi i mačke: 8 mg cefovecina/kg tjelesne težine (1 ml/10 kg tjelesne težine).
Dogs and cats: The safety of the veterinary medicinal product has not been established during pregnancy and lactation (See section 4.3).
Psi i mačke: Neškodljivost ovog veterinarsko-medicinskog proizvoda za vrijeme graviditeta i laktacije nije utvrđena (vidjeti dio 4.3).
Dogs and cats: The safety of the veterinary medicinal product has not been established during pregnancy and lactation.
Psi i mačke: Neškodljivost ovog veterinarsko-medicinskog proizvoda za vrijeme graviditeta i laktacije nije utvrđena.
Dogs less than 5 kg Dogs 5 to 10 kg Dogs 10 to 20 kg Dogs 20 to 40 kg Dogs 40 to 60 kg
Psi lakši od 5 kg Psi od 5 do 10 kg Psi od 10 do 20 kg Psi od 20 do 40 kg Psi od 40 do 60 kg
Dogs may very rarely show short-lived redness, itching or other signs of discomfort at the application site.
U pasa se vrlo rijetko manifestiralo kratkoročno crvenilo, svrbež ili neugoda u mjesto primjene.
Dogs may very rarely vomit or have diarrhoea.
Psi mogu vrlo rijetko povraćati ili imati proljev.
Dogs over 10 kg and up to 40 kg body weight
Psi tjelesne težine između 10 i 40 kg
Dogs over 4 kg and up to 10 kg body weight
Psi tjelesne težine između 4 i 10 kg
Dogs receiving APOQUEL tablets should therefore be monitored for the development of infections and neoplasia.
Pse koji primaju APOQUEL tablete treba promatrati zbog razvoja infekcija i neoplazija.
Dogs should be dosed daily.
Psima proizvod treba davati svakodnevno.
Dogs should not be allowed to swim in surface waters for 4 days after treatment.
Psima treba onemogućiti da se kupaju u otvorenim vodama 4 dana nakon tretiranja.
Dogs should not be used for breeding while under treatment.
Za vrijeme liječenja psi se nesmiju upotrebljavati za rasplod..
Dogs travelling to a heartworm region should start medication within a month after arrival there.
Psima koji putuju u područja u kojima postoji bolest srčanog crva lijek se mora primijeniti unutar mjesec dana od dolaska u takva područja.
Dogs travelling to a heartworm region should start medication within a month after arrival there.
Psima koji putuju u područja u kojima postoji bolest srčanog crva liječenje se mora primijeniti unutar mjesec dana od dolaska u takva područja.
Dogs weighing 10.1–20.0 kg.
Psi tjelesne mase 10,1 – 20,0 kg.
Dogs weighing 2.6–5.0 kg.
Psi tjelesne mase 2,6 – 5,0 kg.
Dogs weighing 20.1–40.0 kg.
Psi tjelesne mase 20,1 – 40,0 kg.
Dogs weighing 40.1–60.0 kg.
Psi tjelesne mase 40,1 – 60,0 kg.
Dogs weighing 5.1–10.0 kg.
Psi tjelesne mase 5,1 – 10,0 kg.
Dogs with Addison’s disease have insufficient levels of aldosterone in their blood and Zycortal is used to replace the missing hormone.
Psi koji boluju od Addisonove bolesti imaju dovoljne količine aldosterona u svojoj krvi, a Zycortal se koristi kao zamjena za hormon koji nedostaje.
Dogs with combined glucocorticoid and mineralocorticoid deficiency should also receive a glucocorticoid such as prednisolone in accordance with standard texts.
Psi s kombinacijom nedostatka glukokortikoida i mineralokortokida također bi trebali primati glukokortikoid kao što je prednizolon u skladu sa standardnim uputama.
Dogs, cats, cattle (calves and young cattle) and pigs
Psi, mačke, goveda (telad i mlada goveda) i svinje
Dogs.
Pas.
Dogs: After an intramuscular dose of 50 micrograms/kg a maximum concentration in plasma of about 12 ng/ml is reached after 0.6 hours.
Psi: Nakon intramuskularne doze od 50 mikrograma/kg, maksimalna koncentracija u plazmi od otprilike 12 nanograma/ml postiže se nakon 0,6 sati.
Dogs: i.v. or s.c.
Psi: i.v. ili s.c.
DOGS: In cases of overdosage, or if the effects of dexmedetomidine become potentially life- threatening, the appropriate dose of atipamezole is 10 times the initial dose of dexmedetomidine (micrograms/ kg bw or micrograms/ square meter body surface area).
Psi: U slučajevima predoziranja ili ako učinci deksmedetomidina postanu potencijalno životno ugrožavajući, prikladna doza atipamezola je 10 puta veća od inicijalne doze deksmedetomidina (mikrogrami/kg tjelesne težine ili mikrogrami/četvornom metru površine tijela).
Dogs: intravenous or intramuscular use
Pse: intravenska ili intramuskularna primjena
Dogs: intravenous or intramuscular use
Pse: intravenska ili intramuskularna primjena.
Dogs: intravenous or intramuscular use Cats: intramuscular use
Psi: intravenska ili intramuskularna primjena Mačke: intramuskularna primjena
Dogs: intravenous or subcutaneous use Cats: subcutaneous use
Psi: za intravenozno ili subkutano davanje Mačke: za subkutano davanje
Dogs: IV or SC.
Psi: i.v. ili s.c.
Dogs: Musculo-skeletal disorders: single subcutaneous injection.
Psi: Mišićno-koštani poremećaji: jedna supkutana injekcija.
Dogs: No adverse reactions other than those described in section 4.6 have been observed following subcutaneous administration of up to 6 times the recommended dose.
Pas; Nuspojave drugačije od onih opisanih u dijelu 4.6 nisu bile zamijećene ni poslije istovremenog apliciranja 6 puta veće doze.
Dogs: single administration of 0.2 mg meloxicam /kg body weight (i.e.
Psi: jedna primjena od 0,2 mg meloksikama/kg tjelesne težine (tj.
Dogs: single administration of 0.2 mg meloxicam/kg body weight (i.e.
Psi: jedna primjena od 0,2 mg meloksikama/kg tjelesne mase (tj.
Dogs: single administration of 0.2 mg meloxicam/kg body weight (i.e.
Psi: jednokratno davanje 0.2 mg meloksikama / kg tjelesne mase (tj.
Dogs: subcutaneous or intravenous use
Psi: supkutana ili intravenska
Dogs: Subcutaneous use.
Subkutana primjena
Dogs: The recommended dose is 15 mg indoxacarb/kg body weight, equivalent to 0.077 ml/kg body weight.
Psi: Preporučena dnevna doza je 15 mg indoksakarba/kg tjelesne mase, što je ekvivalent za 0,077 ml/kg tjelesne mase.
Dolasetron 100 milligrams
Dolazetron 100 miligrama
Dolutegravir
Amprenavir:
Dolutegravir
Nakon obroka
Dolutegravir (50 mg once daily), tenofovir alafenamide (10 mg once daily)3
Dolutegravir (50 mg jedanput na dan), tenofoviralafenamid (10 mg jedanput na dan)3
Dolutegravir 50 mg once daily (daclatasvir 60 mg once daily)
dolutegravir 50 mg jedanput na dan (daklatazvir 60 mg jedanput na dan)
Dolutegravir 50 mg Once Daily + BR N=354§
Dolutegravir 50 mg jedanput na dan + osnovni režim liječenja N=354§
Dolutegravir and other suspect agents should be discontinued immediately if signs or symptoms of hypersensitivity reactions develop (including, but not limited to, severe rash or rash accompanied by raised liver enzymes, fever, general malaise, fatigue, muscle or joint aches, blisters, oral lesions, conjunctivitis, facial oedema, eosinophilia, angioedema).
Primjena dolutegravira i drugih suspektnih lijekova mora se odmah prekinuti ako se pojave znakovi ili simptomi reakcija preosjetljivosti (uključujući između ostaloga, težak osip ili osip praćen povišenim vrijednostima jetrenih enzima, vrućicu, opću malaksalost, umor, tupe bolove u mišićima ili zglobovima, mjehuriće, oralne lezije, konjunktivitis, edem lica, eozinofiliju, angioedem).
dolutegravir C24h 38% dolutegravir Cmax ↓ 11%
dolutegravir AUC ↓ 32% dolutegravir C24h 38% dolutegravir Cmax ↓ 11% darunavir ↔
dolutegravir Cmax ↓ 11% darunavir ↔*
dolutegravir AUC ↓ 32% dolutegravir C24h 38% dolutegravir Cmax ↓ 11% darunavir ↔
Dolutegravir had no pharmacodynamic effect on
Dolutegravir nije utjecao na farmakodinamiku
Dolutegravir has a <10 fold change against 94% of the 705 clinical isolates.
Vrijednost promjene za dolutegravir iznosila je <10 u 94% od 705 kliničkih izolata.
Dolutegravir has a less than or equal to 10 FC against 94% of the 705 clinical isolates.
FC vrijednost dolutegravira iznosila je 10 ili manje u 94% od 705 kliničkih izolata.
dolutegravir is 50 mg twice daily when co-administered with carbamazepine, DTG/ABC/3TC FDC is not recommended for patients taking carbamazepine.
S obzirom da je preporučena doza dolutegravira 50 mg dvaput na dan kad se istodobno primjenjuje s karbamazepinom, fiksna kombinacija dolutegravir/abakavir/lamivudin se ne preporučuje u bolesnika koji uzimaju karbamazepin.
Dolutegravir is also a substrate of UGT1A3, UGT1A9, CYP3A4, P-gp, and BCRP.
Dolutegravir je i supstrat za UGT1A3, UGT1A9, CYP3A4, P-gp te BCRP.
Dolutegravir is also a substrate of UGT1A3, UGT1A9, CYP3A4, Pgp, and BCRP; therefore medicinal products that induce those enzymes may decrease dolutegravir plasma concentration and reduce the therapeutic effect of dolutegravir (see Table 1).
Dolutegravir je i supstrat za UGT1A3, UGT1A9, CYP3A4, P-gp i BCRP; stoga lijekovi koji induciraju navedene enzime mogu smanjiti koncentracije dolutegravira u plazmi i tako oslabiti terapijski učinak dolutegravira (vidjeti Tablicu 1).
Dolutegravir is eliminated mainly through metabolism by UGT1A1.
Dolutegravir se uglavnom eliminira metabolizmom u kojem posreduje UGT1A1.
Dolutegravir may increase plasma concentrations of medical products in which excretion is dependent upon OAT3.
Dolutegravir može povećati plazmatske koncentracije lijekova čije izlučivanje ovisi o OAT3.